NFE2L2 and hepatocellular carcinoma: This is supported by the fact that NRF2 gain of function mutations have been associated with HCC (Cancer Genome Atlas Research Network, 2017; Ngo et al., 2017), chronic NRF2 activation causes hepatomegaly (Komatsu et al., 2010; He et al., 2020), and upregulation of NRF2 has been observed as a biomarker for HCC (Zhang et al., 2015; Bartolini et al., 2018; Mohs et al., 2021).